Roche ROP -1.72%decrease; down pointing triangle Holding said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.

The Swiss pharmaceutical company is seeking to enter the weight-loss drug market that Eli Lilly LLY -0.01%decrease; down pointing triangle and Novo Nordisk NOVO.B -0.24%decrease; down pointing triangle currently dominate, and sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8